Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioVex Ltd.

Division of Amgen Inc.
www.biovex.com

Latest From BioVex Ltd.

British Biotechs Urge U.K. Government To Import French Private Investment Vehicle

British biotech companies want the U.K. government to adopt a French method of funneling funds into the cash-strapped sector from private individuals in return for favorable rates of investment tax, on grounds that a version of France’s long-running Fonds Commun de Placement dans l'Innovation is needed for small-to-medium-sized biopharma companies in Britain to tap successfully into long-term seed capital.

BioPharmaceutical United Kingdom

EU's CHMP Clears Europe's First Gene Therapy, UniQure's Glybera

After three previous negative votes, the Netherlands biotech uniQure gains the first positive opinion from the Committee for Medicinal Products for Human Use for a gene therapy in Europe. Glybera is used to treat the ultra-rare condition lipoprotein lipase deficiency.

BioPharmaceutical Europe

immatics biotechnologies GMBH

immatics biotechnologies GMBH aims to identify tumor-associated peptides by directly measuring their presence in cancer tissue and then creating cancer vaccines from combinations of the most prevalent peptides associated with a particular tumor. The Tuebingen-based firm's proprietary platform combines genomics, mass spectrometry and cell-based assay systems to offer better speed and precision than existing technologies.
BioPharmaceutical Europe

Recent Dealmaking (11/2003)

Summarizing the month in European dealmaking.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Amgen Inc.
  • Senior Management
  • Gareth Beynon, MD, PhD, CEO
    Philip Astley-Sparke, CFO
    Colin Love, PhD, Dev. Dir.
    Robert Coffin, PhD, CSO
  • Contact Info
  • BioVex Ltd.
    Phone: (44) 123 544 1900
    70 Milton Park
    Abingdon, OX14 4RX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register